Letters to Officials
CCAGW Urges House of Representatives to Oppose H.R. 6929
H.R. 6929 would cost taxpayers over $700 million over the next 10 years.
CAGW Shares 2022 Congressional Pig Book With Congress
July 20, 2022 U.S. House of Representatives Washington, D.C. 20515 Dear Representative,
CCAGW Urges Senate to Support S. Con. Res. 43
S. Con. Res. 43 would rein in government spending and reform the budget and appropriations processes.
CCAGW Joins Coalition Opposing Antitrust Legislation
Recent antitrust proposal would dramatically expand the government's regulation authority.
CCAGW Sends Letter to House of Representatives on H.R. 8294
CCAGW urges the House of Representatives to support fiscally responsible amendments to H.R. 8294
CCAGW Sends Letter to House Energy and Commerce Committee Regarding H.R. 8152, the American Data Privacy and Protection Act
The need for a national privacy framework is critical and CCAGW commends the Committee for their work so far.
CCAGW Joins Coalition Urging Caution with F-35 Engine Spending
The F-35 program as a whole has already cost American taxpayers an exorbitant amount.
CCAGW Sends Letter to House of Representatives on H.R. 7900, the National Defense Authorization Act
CCAGW shares thoughts on amendments to the NDAA
CCAGW Joins Coalition Supporting Amendment to National Defense Authorization Act
Rep. Adam Smith's amendment would save more than $4 billion over five years.
CCAGW Joins Coalition Supporting the Middle-Class Savings and Investment Act
The Middle-Class Savings and Investment Act provides targeted tax relief to those most hurt by inflation.
CCAGW Sends Letter on H.R. 8152, the American Data Privacy and Protection Act
June 22, 2022 Chairman Janice Schakowsky and Ranking Member Gus Billirakis Subcommittee on Consumer Protection and Commerce House Energy and Commerce Committee 2125 Rayburn House Office Building Washington, D.C. 20515
CAGW Sends "Drug importation is dangerous and won't lower prices" to Senate HELP Committee
The op-ed concludes that drug importation will risk public health and do little to lower drug prices.
